Výzkumná zpráva Fakultní nemocnice ke klinickému Hodnocení CA209-067

Abstract

A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma

Keywords

• Metastatic Melanoma
• nivolumab
• ipilimumab